Vaccines-2013 - OMICS Group

Recommendations

Info

Satish Gaikwad et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAHSP70 mediated multi-epitope DNA as vaccine candidate for Newcastle disease of poultrySatish Gaikwad, Sohini Dey, R. Saravanan, Nitin M. Kamble, Aravind S. Pillai and C. Madhan MohanIndian Veterinary Research Institute, IndiaNewcastle disease virus is an infectious disease of poultry which causes severe economic losses in domestic poultry. Newgeneration vaccines are currently in demand to avert deficiencies of vaccines currently in market. Among these, rationaldesign of vaccine candidate is a promising approach. Multi-epitopic DNA vaccine construct containing fusion and haemagglutininepitopes were designed with additional elements like endoplasmic reticulum secretory signal sequence, poly histidine and geneoptimization to improve immunogenicity. Mycobacterium tuberculosis HSP70 was used as a genetic adjuvant to increase innateand adaptive immune responses. Transient expression of the construct was confirmed with an immunofluorescent assay in Verocells. The constructs were injected subcutaneously into 15 days-old specific pathogen free chickens. Immune responses werestudied with HI, ELISA, LTT and FACS assays. Protection was assessed by challenging with a virulent virus. HSP mediatedmulti epitopes improved the immune responses and conferred protection against Newcastle disease. The results indicate that arationally designed DNA vaccine construct can improve vaccine strategies involving nucleic acid immunizations.BiographySatish Gaikwad has completed his Ph.D. from IVRI, Izatnagar, Bareilly, UP, India.satish.bty@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 156
Veronica Rainone et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAHPV vaccination in ARV-treated HIV-infected adolescents and young adults induces strongHPV-specific cell-mediated immune responsesVeronica Rainone 1 , Daria Trabattoni 1 , Francesca Penagini 2 , Francesca Dinello 2 , Gian Vincenzo Zuccotti 2 , Vania Giacomet 2 , AlessandraVigano 2 and Mario Clerici 3,41Chair of Immunology, University of Milan, Department of Biomedical and Clinical Sciences L. Sacco, Italy2Department of Pediatrics, L. Sacco Hospital, Italy3Department of Medical Surgical Pathophysiology and Transplant, University of Milan, Italy4Don C. Gnocchi Foundation, ItalyBackground: Human Papilloma Virus (HPV)-associated ano-genital infections represent the most common sexually transmitteddisease in the general population. The incidence of HPV-associated cancers has been increasing in HIV-infected patients.HPV vaccination may be an important approach to reduce the risk of HPV-associated cancers in HIV-infected patients and acombined strategy of screening and HPV vaccination may guarantee a more adequate prevention of HPV-associated lesions.Immunogenicity of HPV vaccines in HIV-infected patients is still not adequately evaluated. We analysed safety, immunogenicityand efficacy of a quadrivalent HPV vaccine in HIV-infected patients without baseline molecular evidence of vaccine-type HPVinfection focusing on HPV-specific cell mediated immunity (CMI).Methods: 31 ARV-treated HIV-infected adolescents (age range 28-14 years, mostly with undetectable viremia and effectiveCD4 recovery) and 25 sex- and age-matched HIV-seronegative healthy controls were enrolled in the study. Quadrivalent HPV-16/18/6/11 VLP vaccine (Gardasil®) was administered at baseline, 2 months and 6 months. Safety was evaluated in terms of rateand severity of vaccine-related adverse events. Immune activation (CD4/CD25/HLADRII, CD8/CD25/HLADRII), naїve andmemory T-cell patterns and HPV-specific immune responses (CD4/IFN-γ/IL-2, CD8/IFN-γ/TNF-γ, CD8/Perforin/GranzymeB)were evaluated at baseline and after vaccine administrations.Results: Results obtained after the first immunization in HIV-infected individuals show: 1) no changes in CD4 counts, percentageof CD4 cells and HIV viral load; 2) a significant increase in naїve CD8 T-cells, activated CD8 T-cells and in central memoryCD4 and CD8 T-cells; 3) a significant reduction in terminally differentiated CD8 T-cells; and 4) a significant augmentationof unstimulated and HPV-specific IL2+/CD4+, IFN-γ+/CD4+, IFN-γ+/CD8+ and TNF-α+/CD8+ T-cells. No differences wereobserved in Perforin- or Granzyme B-secreting CD8 T-cells. Similar results were obtained in healthy controls.Conclusions: Quadrivalent HPV-16/18/6/11 VLP vaccine induces strong HPV-specific cell-mediated immune responses inARV-treated HIV-infected individuals that are comparable to those observed in HIV-seronegative controls. HPV-specific CMI islikely an important component of the protective effect of this vaccine, data herein indicating that this component is not impairedin ARV-treated HIV infected individuals.veronica.rainone@unimi.itJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 157
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74:
Young Research ForumSession ChairPe
Page 75 and 76:
Humberto Hernandez et al., J Vaccin
Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90:
Obradovic Zarema et al., J Vaccines
Page 91 and 92:
Abdur Razzaque Sarker et al., J Vac
Page 93 and 94:
Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96:
Page 97 and 98:
Regina Heidenreich et al., J Vaccin
Page 99 and 100:
Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102:
Zafer Kurugol et al., J Vaccines Va
Page 103 and 104:
Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 117 and 118: 111 th OMICS Group Conference3 rd I
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142: 111 th OMICS Group Conference3 rd I
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155: Sandeepkumar R. Chauhan et al., J V
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?